Sign In
to Vote &
Create Storyboards.
 
A new study published online in the American Journal of Obstetrics and Gynecology by researchers from the University of Pittsburgh School of Medicine and the University of Pittsburgh School of Pharmacy reports that 17-hydroxyprogesterone caproate (17-OHPC), a medication that reduces the rate of preterm birth in high-risk women, did not raise any safety concerns when the medication was prepared and dispensed by independent compounding pharmacies throughout the United States...
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard